WO2001012187A3 - Benzoic acid derivatives and their use as ppar receptor agonists - Google Patents

Benzoic acid derivatives and their use as ppar receptor agonists Download PDF

Info

Publication number
WO2001012187A3
WO2001012187A3 PCT/GB2000/003140 GB0003140W WO0112187A3 WO 2001012187 A3 WO2001012187 A3 WO 2001012187A3 GB 0003140 W GB0003140 W GB 0003140W WO 0112187 A3 WO0112187 A3 WO 0112187A3
Authority
WO
WIPO (PCT)
Prior art keywords
benzoic acid
acid derivatives
receptor agonists
ppar receptor
ppar
Prior art date
Application number
PCT/GB2000/003140
Other languages
French (fr)
Other versions
WO2001012187A2 (en
Inventor
Rodney Brian Hargreaves
Paul Robert Owen Whittamore
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Ltd
Rodney Brian Hargreaves
Paul Robert Owen Whittamore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU65834/00A priority Critical patent/AU6583400A/en
Priority to CA002380775A priority patent/CA2380775A1/en
Priority to BR0013368-0A priority patent/BR0013368A/en
Priority to MXPA02001598A priority patent/MXPA02001598A/en
Priority to NZ517059A priority patent/NZ517059A/en
Priority to JP2001516533A priority patent/JP2003507327A/en
Application filed by Astrazeneca Ab, Astrazeneca Uk Ltd, Rodney Brian Hargreaves, Paul Robert Owen Whittamore filed Critical Astrazeneca Ab
Priority to EP00953320A priority patent/EP1210343A2/en
Priority to IL14782100A priority patent/IL147821A0/en
Priority to KR1020027002019A priority patent/KR20020020817A/en
Publication of WO2001012187A2 publication Critical patent/WO2001012187A2/en
Publication of WO2001012187A3 publication Critical patent/WO2001012187A3/en
Priority to NO20020765A priority patent/NO20020765L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention relates to the use of certain benzoic acid derivatives of formula (I), where the substituents are as defined in the specification, which act as peroxisome proliferator activated receptor (PPAR) agonists, in particular gamma receptors (PPARη), and so are useful in the treatment of states of insulin resistance, including type 2 diabetes mellitus.
PCT/GB2000/003140 1999-08-18 2000-08-14 Benzoic acid derivatives and their use as ppar receptor agonists WO2001012187A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA002380775A CA2380775A1 (en) 1999-08-18 2000-08-14 Benzoic acid derivatives and their use as ppar receptor agonists
BR0013368-0A BR0013368A (en) 1999-08-18 2000-08-14 Use of a compound, compound, and pharmaceutical composition
MXPA02001598A MXPA02001598A (en) 1999-08-18 2000-08-14 Chemical compounds.
NZ517059A NZ517059A (en) 1999-08-18 2000-08-14 Indole derivatives of benzoic acid which act as peroxisome proliferator activated receptor (PPAR)
JP2001516533A JP2003507327A (en) 1999-08-18 2000-08-14 Chemical compound
AU65834/00A AU6583400A (en) 1999-08-18 2000-08-14 Chemical compounds
EP00953320A EP1210343A2 (en) 1999-08-18 2000-08-14 Benzoic acid derivatives and their use as ppar receptor agonists
IL14782100A IL147821A0 (en) 1999-08-18 2000-08-14 Benzoic acid derivatives and their use as ppar receptor agonists
KR1020027002019A KR20020020817A (en) 1999-08-18 2000-08-14 Chemical Compounds
NO20020765A NO20020765L (en) 1999-08-18 2002-02-15 Chemical connections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9919411.0 1999-08-18
GBGB9919411.0A GB9919411D0 (en) 1999-08-18 1999-08-18 Chemical compounds

Publications (2)

Publication Number Publication Date
WO2001012187A2 WO2001012187A2 (en) 2001-02-22
WO2001012187A3 true WO2001012187A3 (en) 2001-06-07

Family

ID=10859283

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/003140 WO2001012187A2 (en) 1999-08-18 2000-08-14 Benzoic acid derivatives and their use as ppar receptor agonists

Country Status (14)

Country Link
EP (1) EP1210343A2 (en)
JP (1) JP2003507327A (en)
KR (1) KR20020020817A (en)
CN (1) CN1379774A (en)
AU (1) AU6583400A (en)
BR (1) BR0013368A (en)
CA (1) CA2380775A1 (en)
GB (1) GB9919411D0 (en)
IL (1) IL147821A0 (en)
MX (1) MXPA02001598A (en)
NO (1) NO20020765L (en)
NZ (1) NZ517059A (en)
WO (1) WO2001012187A2 (en)
ZA (1) ZA200200669B (en)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495949B1 (en) 1999-11-03 2002-12-17 Orion Electric Co., Ltd. Electron tube cathode
US6503907B2 (en) * 2000-11-28 2003-01-07 Hoffmann-La Roche Inc. Indole and dihydroindole derivatives
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
US7291639B2 (en) 2001-06-20 2007-11-06 Wyeth Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
ATE367812T1 (en) 2001-06-20 2007-08-15 Wyeth Corp SUBSTITUTED INDOLIC ACID DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1)
WO2003035602A1 (en) * 2001-10-25 2003-05-01 Sankyo Company, Limited Lipid modulators
ATE433440T1 (en) 2002-02-05 2009-06-15 Lilly Co Eli UREA LINK COMPOUNDS AND THEIR USE AS PPAR REGULATORS
JP3782818B2 (en) 2002-06-20 2006-06-07 アストラゼネカ アクチボラグ Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
SE0201937D0 (en) * 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
BR0316574A (en) 2002-12-10 2005-10-04 Wyeth Corp Substituted 3-carbonyl-1h-indol-1-yl acetic acid derivatives as plasminogen activator inhibitor-1 inhibitors (parent-1)
DE60324183D1 (en) 2002-12-10 2008-11-27 Wyeth Corp Aryl-, aryloxy- und alkyloxysubstituierte 1h-indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
US7056943B2 (en) 2002-12-10 2006-06-06 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
EP1569899B1 (en) 2002-12-10 2006-06-28 Wyeth Substituted 3-alkyl- and 3-arylalkyl-1h-indol-1-yl-acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
DE10308352A1 (en) * 2003-02-27 2004-09-09 Aventis Pharma Deutschland Gmbh Branched side chain arylcycloalkyl derivatives, process for their preparation and their use as medicaments
TWI289141B (en) 2003-03-11 2007-11-01 Hoffmann La Roche F. Ag. Quinolinone derivatives and uses thereof
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
WO2004096767A1 (en) * 2003-04-25 2004-11-11 H. Lundbeck A/S Sustituted indoline and indole derivatives
JP4895811B2 (en) 2003-09-11 2012-03-14 ケミア，インコーポレイテッド Cytokine inhibitor
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
CN101039936A (en) 2004-08-23 2007-09-19 惠氏公司 Oxazolo-naphthyl acids as plasminogen activator inhibitor type-1(pai-1) modulators useful in the treatment of thrombosis and cardiovascular diseases
EP1807398B1 (en) * 2004-10-27 2008-06-25 F. Hoffmann-Roche AG New indole or benzimidazole derivatives
JP5833804B2 (en) 2005-04-13 2015-12-16 ニューラクソン，インコーポレーテッド Substituted indole compounds having NOS inhibitory activity
EP1919866A2 (en) 2005-08-17 2008-05-14 Wyeth a Corporation of the State of Delaware Substituted indoles and use thereof
US8686002B2 (en) 2005-08-21 2014-04-01 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as binding partners for 5-HT5 receptors
CA2643822A1 (en) * 2006-04-13 2007-10-25 Neuraxon, Inc 1,5 and 3,6- substituted indole compounds having nos inhibitory activity
JP2009536954A (en) 2006-05-11 2009-10-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 3,4-Dihydro-2H-benzo [1,4] oxazine and thiazine derivatives as CETP inhibitors
EP2034998A1 (en) 2006-05-11 2009-03-18 Janssen Pharmaceutica, N.V. 1,2,3,4-tetrahydro-quinoline derivatives as cetp inhibitors
US7432255B2 (en) * 2006-05-16 2008-10-07 Hoffmann-La Roche Inc. 1H-indol-5-yl-piperazin-1-yl-methanone derivatives
WO2008020302A2 (en) * 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
WO2008109336A1 (en) 2007-03-01 2008-09-12 Janssen Pharmaceutica N.V. Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor
CA2680275C (en) 2007-03-09 2016-08-23 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
AU2008270784A1 (en) * 2007-07-02 2009-01-08 Glaxosmithkline Llc Farnesoid X receptor agonists
FR2921366B1 (en) * 2007-09-26 2009-12-04 Servier Lab NOVEL HETEROCYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
AU2008323526A1 (en) 2007-11-16 2009-05-22 Neuraxon, Inc. Indole compounds and methods for treating visceral pain
WO2009100294A2 (en) 2008-02-07 2009-08-13 Abbott Laboratories Amide derivatives as positive allosteric modulators and methods of use thereof
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
PL3400944T3 (en) 2010-11-08 2020-11-16 Albireo Ab Ibat inhibitors for the treatment of liver diseases
US20130236541A1 (en) 2010-11-08 2013-09-12 Albireo Ab Pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
US8957093B2 (en) 2011-06-06 2015-02-17 The Scripps Research Institute N-biphenylmethylindole modulators of PPARG
US9051265B2 (en) * 2011-06-06 2015-06-09 The Scripps Research Institute N-benzylindole modulators of PPARG
WO2013019682A1 (en) * 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Compounds and methods
US9309227B2 (en) 2011-11-22 2016-04-12 The Scripps Research Institute N-biphenylmethylbenzimidazole modulators of PPARG
WO2013096496A2 (en) 2011-12-21 2013-06-27 Allergan, Inc. Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
WO2013159095A1 (en) * 2012-04-20 2013-10-24 Anderson Gaweco Ror modulators and their uses
EP2844259A4 (en) 2012-04-30 2015-11-11 Anderson Gaweco Ror modulators and their uses
CN104788358A (en) * 2014-01-20 2015-07-22 中国科学院上海药物研究所 N-(3-fluoro-4-chlorobenzyl)indole derivative and use thereof
KR101585605B1 (en) * 2014-03-20 2016-01-21 현대약품 주식회사 Compounds that binding with PPARG(Peroxisome Proliferator Activated Receptor-Gamma) but not act as an agonist and pharmaceutical composition for diseases related with PPARG containing the same as an active ingredient
WO2015161108A1 (en) 2014-04-16 2015-10-22 The Scripps Research Institute Pparg modulators for treatment of osteoporosis
CN107176914B (en) * 2016-03-09 2022-06-28 浙江旭晨医药科技有限公司 GVS series compound and its use
KR20200010483A (en) * 2017-05-26 2020-01-30 메드샤인 디스커버리 아이엔씨. Lactam Compounds as FXR Receptor Agonists
WO2020045982A1 (en) * 2018-08-29 2020-03-05 숙명여자대학교산학협력단 SUBSTITUTED INDOLE DERIVATIVE, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH PPARα, PPARγ, AND PPARδ
JP7323603B2 (en) * 2018-09-07 2023-08-08 メッドシャイン ディスカバリー インコーポレイテッド Tricyclic Fused Furan-Substituted Piperidinedione Compounds

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0179619A1 (en) * 1984-10-19 1986-04-30 Ici Americas Inc. Heterocyclic amides
US4894386A (en) * 1987-04-15 1990-01-16 Ici Americas Inc. Aliphatic carboxamides
WO1997005114A1 (en) * 1995-07-31 1997-02-13 Laboratorios Menarini S.A. Quinolone sulfonimides having leukotriene-antagonistic action
EP0780389A1 (en) * 1995-12-22 1997-06-25 Tobishi Pharmaceutical Co., Ltd. Thiazolidinedione derivatives, process for their preparation and pharmaceutical compositions containing them
WO1998051667A1 (en) * 1997-05-16 1998-11-19 Chugai Seiyaku Kabushiki Kaisha Indole derivatives and mono- and diazaindole derivatives
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0179619A1 (en) * 1984-10-19 1986-04-30 Ici Americas Inc. Heterocyclic amides
US4894386A (en) * 1987-04-15 1990-01-16 Ici Americas Inc. Aliphatic carboxamides
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
WO1997005114A1 (en) * 1995-07-31 1997-02-13 Laboratorios Menarini S.A. Quinolone sulfonimides having leukotriene-antagonistic action
EP0780389A1 (en) * 1995-12-22 1997-06-25 Tobishi Pharmaceutical Co., Ltd. Thiazolidinedione derivatives, process for their preparation and pharmaceutical compositions containing them
WO1998051667A1 (en) * 1997-05-16 1998-11-19 Chugai Seiyaku Kabushiki Kaisha Indole derivatives and mono- and diazaindole derivatives

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BIOORG. MED. CHEM. LETT., vol. 8, no. 21, - 1998, pages 3053 - 3058 *
CHEMICAL ABSTRACTS, vol. 130, no. 9, 1 March 1999, Columbus, Ohio, US; abstract no. 110138m, HULME, CHRISTOPHER ET AL.: "Orally active indole N-oxide PDE4 inhibitors." XP002158920 *
DATABASE CHEMICAL ABSTRACTS XP002158921 *
R GRIERA ET AL.: "Synthesis and pharmacological evaluation of new cysLT1 receptor antagonists", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.CHIMICA THERAPEUTICA., vol. 32, - 1997, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS., FR, pages 547 - 570, XP002158918, ISSN: 0223-5234 *
ROBERT T. JACOBS ET AL.: "Substituted 3-(phenylmethyl)-1H-indole-5-carboxamides and 1-(phenylmethyl)indole-6-carboxamides as potent, selective, orally active antagonists of the peptidoleukotrienes", JOURNAL OF MEDICINAL CHEMISTRY., vol. 36, no. 3, - 1993, AMERICAN CHEMICAL SOCIETY. WASHINGTON., US, pages 394 - 409, XP002158919, ISSN: 0022-2623 *
ROBERT T. JACOBS ET AL.: "Synthesis, structure-activity relationships, and pharmacological evaluation of a series of fluorinated 3-benzyl-5-indolecarboxamides: identification of 4-((5-(((2R)-2-methyl-4,4,4,-trifluorobutyl)carbamoyl)-1-methylindol-3-yl)methyl)-3-methoxy-N-((2-methylphenyl)sulfonyl)benzamide, ...", JOURNAL OF MEDICINAL CHEMISTRY., vol. 37, no. 9, - 1994, AMERICAN CHEMICAL SOCIETY. WASHINGTON., US, pages 1282 - 1297, XP002158917, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
BR0013368A (en) 2002-05-07
IL147821A0 (en) 2002-08-14
WO2001012187A2 (en) 2001-02-22
NO20020765D0 (en) 2002-02-15
NZ517059A (en) 2004-05-28
NO20020765L (en) 2002-04-17
EP1210343A2 (en) 2002-06-05
CN1379774A (en) 2002-11-13
JP2003507327A (en) 2003-02-25
AU6583400A (en) 2001-03-13
ZA200200669B (en) 2003-06-25
MXPA02001598A (en) 2002-07-02
KR20020020817A (en) 2002-03-15
GB9919411D0 (en) 1999-10-20
CA2380775A1 (en) 2001-02-22

Similar Documents

Publication Publication Date Title
WO2001012187A3 (en) Benzoic acid derivatives and their use as ppar receptor agonists
HUP0201654A2 (en) Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor (ppar) alpha, their preparation and pharmaceutical composition containing the same
NZ515902A (en) Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, and type 2 diabetes
HK1068604A1 (en) Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
AU2804400A (en) Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists
NO20020764D0 (en) Benzoic acid derivatives for the treatment of diabetes mellitus
IL175310A0 (en) Phenoxyacetic acids derivatives useful as peroxisome proliferator-activated receptor (ppar) dual agonists
BR0211414A (en) Compound, use thereof, pharmaceutical composition, and methods for treating and / or preventing nuclear receptor-mediated conditions and type i diabetes, type ii diabetes, impaired glucose tolerance, insulin resistance or obesity
HRP20010514B1 (en) Telmisartan polymorphs, methods for producing same and their use in the preparation of a medicament
NO20052575L (en) New compounds, their preparation and use
HUP0402486A3 (en) Nitrogen containing heterocyclic compounds as peroxisome proliferator activated receptor agonists, their use and pharmaceutical compositions cointaining them
HK1083021A1 (en) Substituted arylalcanoic acid derivatives as ppar pan agonists with potent antihyperglycemic and antihyperlipidemic activity
NZ516290A (en) Substituted phenoxyacetic acids
WO2002044113A3 (en) Use of(-) (3-halomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
PL378130A1 (en) 3-(2-phenyl-oxazol-4-yl methoxy) cyclohexylmethoxy acetic acid derivatives and related compounds used as ppar modulators for treating type 2 diabetes and arteriosclerosis
WO2004041802A8 (en) 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders
ES2156574A1 (en) Thiazolidinedione derivatives as antidiabetic agents
ATE475642T1 (en) PHENOXYACETIC ACID DERIVATIVES AS PPAR AGONISTS
EP1508566A4 (en) (2s)-2-ethylphenylpropionic acid derivative
DK0785787T3 (en) Use of 1,5-benzodiazepine derivatives to control gastric emptying in patients with non-insulin-dependent diabetes mellitus
AU2003238249A1 (en) USE OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR (PPAR)-Gamma LIGANDS AS A TREATMENT FOR PITUITARY TUMORS AND ASSOCIATED CONDITIONS, SUCH AS CUSHING'S SYNDROME
WO2000045894A3 (en) Use of pyrazole carboxamides
DE60000790T2 (en) [(2-SUBSTITUTED-5- [3-THIENYL) -BENZYL] - [2 - ([2-ISOPROPOXY-5-FLUORO] -PHENOXY) -ETHYL] -AMINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINE
TR199501115A2 (en) Double rotary oxazole and thiazole substituted ethers.
PT1778655E (en) 2 - { - 3 2 - (phenyl)-oxazol-4-ylmethoxyl-cyclohexylmethoxy}-propionic acid derivatives used as ppar ligands (peroxisome proliferator-activated receptors) for the treatment of hyperlipidaemie and diabetes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2002/00669

Country of ref document: ZA

Ref document number: 147821

Country of ref document: IL

Ref document number: 200200669

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 65834/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000953320

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2380775

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 517059

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/001598

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020027002019

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1020027002019

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 008143366

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2000953320

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 517059

Country of ref document: NZ

WWW Wipo information: withdrawn in national office

Ref document number: 2000953320

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 517059

Country of ref document: NZ